546 results on '"Boos, Joachim"'
Search Results
2. Physical Activity, Exercise and Sports in Young Cancer Patients
3. Neue AWMF-S2k-Leitlinie Bewegungsförderung und Bewegungstherapie in der pädiatrischen Onkologie
4. Physical Activity, Exercise and Sports in Young Cancer Patients
5. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
6. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow–Berlin 2002
7. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring
8. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
9. Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure
10. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study
11. Data from Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
12. Supplementary Figure 4 from Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
13. Supplementary Figure 2 from Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
14. Supplementary Figure 3 from Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
15. Supplementary Figure 1 from Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
16. Supplementary Table 1 from Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
17. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring
18. Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000
19. Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol
20. Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia
21. Towards a Model-Based Dose Recommendation for Doxorubicin in Children
22. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial
23. Drug Delivery and Formulations
24. Multidisciplinary Network ActiveOncoKids guidelines for providing movement and exercise in pediatric oncology: Consensus‐based recommendations
25. Therapeutic Drug Monitoring of Asparaginase Activity—Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial
26. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors
27. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer
28. Metronomic oral maintenance chemotherapy in patients with localized high-risk rhabdomyosarcoma (RMS) and RMS-like tumors: A report from a randomized, multicenter, phase III trial CWS-2007HR.
29. Erkrankungen im Kindesalter
30. Pharmacokinetics of Anticancer Drugs In Vitro
31. Motor performance in children and adolescents with cancer at the end of acute treatment phase
32. Pharmakologische und arzneimittelrechtliche Probleme im Kindesalter
33. Pharmakologische und arzneimittelrechtliche Probleme im Kindesalter
34. Nephrotoxicity of Ifosfamide in Children
35. Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
36. Adverse events during supervised exercise interventions in pediatric oncology - a nationwide survey
37. Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing
38. One in Four Questioned Children Faces Problems Regarding Reintegration Into Physical Education at School After Treatment for Pediatric Cancer
39. Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration
40. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults
41. Adverse Events During Supervised Exercise Interventions in Pediatric Oncology—A Nationwide Survey
42. Reply: Should we encourage exercise and sports in children and adolescents with cancer?
43. The effect of individualized exercise interventions during treatment in pediatric patients with a malignant bone tumor
44. Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis
45. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children
46. Pediatric patients with a malignant bone tumor: when does functional assessment make sense?
47. Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs
48. Experience of Barriers and Motivations for Physical Activities and Exercise During Treatment of Pediatric Patients With Cancer
49. Comparison of self-reported physical activity in children and adolescents before and during cancer treatment
50. Evaluation of Effects of Busulfan and DMA on SOS in Pediatric Stem Cell Recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.